2nd Circ. Revives Pfizer Securities Suit Over Drug Risks
The Second Circuit on Tuesday revived a securities class action against Pfizer over the alleged hidden health risks of two of its drugs, saying the lower court had improperly excluded an...To view the full article, register now.
Already a subscriber? Click here to view full article